Get ready to move over, Sanofi. A slew of Big Pharma rivals are reportedly weighing their own bids for buyout target Medivation.
Novartis, Pfizer and AstraZeneca are all exploring pitching a counteroffer for the San Francisco drugmaker, which Friday rejected a $9.3 billion buyout bid from the French pharma giant, Bloomberg reports. The trio is conferring with advisers about Medivation’s value, and whether and how to move forward, though there’s no guarantee they’ll come through with their own proposals.
Astellas, which markets star Medivation cancer drug Xtandi, could also jump into the mix, analysts have predicted.
Of course, Sanofi–which saw its $52.50-per-share bid snubbed–could always raise its offer. Still, despite its desire to boost its oncology portfolio, the French drugmaker is wary of overpaying, Bloomberg’s sources say. Medivation–which said the bid substantially undervalued its business–is looking for bids of at least $65 per share, the news service reports, and analysts including Leerink Partners’ Geoffrey Porges and Canaccord Genuity’s David Evanson have estimated value as high as $70.
It’s no surprise multiple drugmakers are giving Medivation a look, considering how many companies have stated a desire to expand in oncology. After last year snagging GlaxoSmithKline’s cancer drugs in a multibillion-dollar asset swap, Novartis has a big focus on the field, and Pfizer could once again be looking to bulk up its three operating units in the wake of its canceled deal with Allergan.
Meanwhile, AstraZeneca has been looking to the cancer arena to help spark the revenue turnaround CEO Pascal Soriot has been promising.
Xtandi could help any of them toward achieving their goals. The prostate cancer therapy’s sales–shared with Astellas–rang up at $1.9 billion worldwide last year, and analysts predict the med will eventually overtake first-to-market competitor pill Zytiga from Johnson & Johnson.
By Carly Helfand
Source: Fierce Pharma
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.